ABT
SP100NYSEAbbott Laboratories
Healthcare · Medical Devices · United States
Abbott Laboratories, together with its subsidiaries, discovers, develops, manufactures, and sells health care products worldwide. It operates in four segments: Established Pharmaceutical Products, Diagnostic Products, Nutritional Products, and Medical Devices. The company offers generic pharmaceuticals for the treatment of pancreatic exocrine insufficiency, irritable bowel syndrome or biliary spasm, intrahepatic cholestasis or depressive symptoms, gynecological disorder, hormone replacement therapy, dyslipidemia, hypertension, hypothyroidism, hypertriglyceridemia, Ménière's disease and vestibular vertigo, pain, fever, inflammation, and migraine, as well as provides anti-infective clarithromycin, influenza vaccine, and products to regulate physiological rhythm of the colon. It also provides laboratory and transfusion medicine systems in the areas of immunoassay, clinical chemistry, hematology, and transfusion serology testing; molecular diagnostics polymerase chain reaction instrument systems that automate the extraction, purification, and preparation of DNA and RNA from patient samples, and detect and measure infectious agents; point of care systems; cartridges for testing blood gas, chemistry, electrolytes, coagulation, and immunoassay; rapid diagnostics lateral flow testing products; molecular point-of-care testing for HIV, SARS-CoV-2, influenza A and B, RSV, and strep A; cardiometabolic test systems; and drug and alcohol test. In addition, the company offers pediatric and adult nutritional products and infant formula; rhythm management, electrophysiology, heart failure, vascular, and structural heart devices for the treatment of cardiovascular diseases; diabetes care products, such as glucose and blood glucose monitoring systems; and neuromodulation devices. The company was formerly known as Abbott Alkaloidal Company and changed its name to Abbott Laboratories in 1915. Abbott Laboratories was founded in 1888 and is based in Abbott Park, Illinois.
www.abbott.com ↗Shares trade at a premium 26.7× trailing earnings, easing to 15.7× on forward estimates. Profitability shows a net margin of 13.9% and return on equity of 12.3%. Leverage is elevated at 2.3× net debt/EBITDA. Revenue grew 7.8% year-on-year. It yields 2.6% in dividends. The mean analyst target of USD116.72 sits 22.3% above the current price (Buy, 25 analysts).
business model
Abbott is a diversified healthcare company that sells medical devices, diagnostics, branded generic pharmaceuticals, and nutrition products to hospitals, labs, pharmacies, retailers, and consumers worldwide. It earns recurring revenue from consumables (e.g., diagnostic tests, continuous glucose monitor sensors) alongside device and product sales.
revenue segments
Four segments: Medical Devices (including the FreeStyle Libre CGM, cardiovascular, and diabetes care), Diagnostics (core lab, molecular, point-of-care, and rapid tests), Established Pharmaceuticals (branded generics sold largely in emerging markets), and Nutrition (Similac infant formula, Ensure adult nutrition). Revenue is geographically diversified across the US and international markets, with strong emerging-market exposure.
key dependencies
Depends on FDA and global regulatory clearances, hospital and lab capital and testing budgets, reimbursement coverage, and global supply chains for components and raw materials. COVID-19 testing demand was a temporary swing factor, and infant-formula operations are sensitive to plant quality and safety oversight.
competitors
Competes with Medtronic, Boston Scientific, Dexcom, and Edwards in devices; Roche, Danaher, Siemens Healthineers, Thermo Fisher, and bioMerieux in diagnostics; and Danone, Nestle, and Reckitt in nutrition.
moat
Moat comes from brand strength, a large installed base of diagnostic instruments that pull recurring test volume, the leading FreeStyle Libre CGM franchise, regulatory approvals, and broad geographic and product diversification that smooths cyclicality.
risks
Risks include competitive and reimbursement pressure (notably in CGM), declining COVID-testing revenue, product recalls and litigation (including infant-formula NEC lawsuits), FX exposure from large international sales, and regulatory or quality issues at manufacturing sites.
Financials & metrics
as of 25 Aug 2026Price is around the middle of its range. Green = nearer the yearly low, red = nearer the high — a position indicator, not a buy/sell signal.
Tap any metric for an explanation.● provider● computedN/A not available from source
Valuation history is being recorded
We snapshot P/E and price targets daily. This chart fills in over the coming days.
Full financial statements
Income statement
| Line item | 2025 | 2024 | 2023 | 2022 | 2021 |
|---|---|---|---|---|---|
| Total revenue | $44.33B | $41.95B | $40.11B | $43.65B | — |
| Cost of revenue | $19.32B | $18.71B | $17.98B | $19.14B | — |
| Gross profit | $25.01B | $23.24B | $22.13B | $24.51B | — |
| Operating expense | $16.96B | $16.42B | $15.66B | $16.15B | — |
| R&D | $2.94B | $2.84B | $2.74B | $2.89B | — |
| Operating income | $8.05B | $6.83B | $6.48B | $8.36B | — |
| Interest expense | $493.00M | $559.00M | $637.00M | $558.00M | — |
| Pretax income | $8.47B | $7.01B | $6.66B | $8.31B | — |
| Tax provision | $1.94B | -$6.39B | $941.00M | $1.37B | — |
| Net income | $6.52B | $13.40B | $5.72B | $6.93B | — |
| EBITDA | $12.07B | $10.79B | $10.54B | $12.13B | — |
| Diluted EPS | $3.72 | $7.64 | $3.26 | $3.91 | — |
Balance sheet
| Line item | 2025 | 2024 | 2023 | 2022 | 2021 |
|---|---|---|---|---|---|
| Total assets | $86.71B | $81.41B | $73.21B | $74.44B | — |
| Current assets | $26.00B | $23.66B | $22.67B | $25.22B | — |
| Cash & equivalents | $8.52B | $7.62B | $6.90B | $9.88B | — |
| Inventory | $6.49B | $6.19B | $6.57B | $6.17B | — |
| Total liabilities | $33.94B | $33.51B | $34.39B | $37.53B | — |
| Current liabilities | $16.50B | $14.16B | $13.84B | $15.49B | — |
| Total debt | $13.86B | $15.02B | $15.63B | $17.72B | — |
| Long-term debt | $9.90B | $12.63B | $13.60B | $14.52B | — |
| Shareholders' equity | $52.13B | $47.66B | $38.60B | $36.69B | — |
| Retained earnings | $49.78B | $47.26B | $37.55B | $35.26B | — |
| Working capital | $9.50B | $9.50B | $8.83B | $9.73B | — |
Cash flow
| Line item | 2025 | 2024 | 2023 | 2022 | 2021 |
|---|---|---|---|---|---|
| Operating cash flow | $9.57B | $8.56B | $7.26B | $9.58B | — |
| Investing cash flow | -$2.42B | -$2.34B | -$3.13B | -$1.74B | — |
| Financing cash flow | -$6.31B | -$5.40B | -$7.09B | -$7.64B | — |
| Capital expenditure | -$2.17B | -$2.21B | -$2.20B | -$1.78B | — |
| Free cash flow | $7.39B | $6.35B | $5.06B | $7.80B | — |
| Dividends paid | -$4.12B | -$3.84B | -$3.56B | -$3.31B | — |
| Share buybacks | -$893.00M | -$1.29B | -$1.23B | -$3.79B | — |
| End cash position | $8.52B | $7.62B | $6.90B | $9.88B | — |
Reported figures from public filings via Yahoo Finance. Line coverage varies by company. Not investment advice.
Dividends
Analyst assessment
as of 25 Aug 2026Aggregate consensus only. Named per-analyst targets require a premium source and are not shown; the data model is ready to hold them if one is added.
Technicals
as of 25 Aug 2026News
Sector peers
Notes & alerts
Sign in to keep a private research note and set price alerts for ABT.